A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation
X Chen, L Tai, J Gao, J Qian, M Zhang, B Li… - Journal of Controlled …, 2015 - Elsevier
Abstract Antagonizing MDM2 and MDMX to activate the tumor suppressor protein p53 is an
attractive therapeutic paradigm for the treatment of glioblastoma multiforme (GBM).
However, challenges remain with respect to the poor ability of p53 activators to efficiently
attractive therapeutic paradigm for the treatment of glioblastoma multiforme (GBM).
However, challenges remain with respect to the poor ability of p53 activators to efficiently
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论